Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 7/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28918756 | 1.00 | SYK (0.49) | SYKACACBSUV39H2PDE10AITGB2 | |
| SCHEMBL22499976 | 0.87 | SYK (0.51) | SYKACACBSUV39H2PDE10AITGB2 | |
| SCHEMBL28605619 | 0.83 | SYK (0.53) | SYKSUV39H2PDE10AITGB2ICAM1 | |
| SCHEMBL28605622 | 0.83 | SYK (0.53) | SYKSUV39H2PDE10AITGB2ICAM1 | |
| SCHEMBL23174126 | 0.83 | SUV39H2 (0.49) | SYKSUV39H2PDE10ACKS1BSKP1 | |
| SCHEMBL23173654 | 0.83 | SUV39H2 (0.49) | SYKSUV39H2PDE10ACKS1BSKP1 | |
| SCHEMBL31536320 | 0.83 | SUV39H2 (0.49) | SYKSUV39H2PDE10ACKS1BSKP1 | |
| SCHEMBL16691339 | 0.81 | SUV39H2 (0.51) | SYKSUV39H2PDE10ACKS1BSKP1 | |
| SCHEMBL2271310 | 0.81 | CKS1B (0.49) | SYKACACBSUV39H2PDE10ACKS1B | |
| SCHEMBL28918751 | 0.80 | ACACB (0.53) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| CN-113164461-A | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | SYK 4147/4885ACACB 3261/4885SUV39H2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.